glp-1 gip dual agonist GIPR/GLP-1R therapies for diabetes and weight loss—chemistry, physiology, and clinical applications Dual GLP-1/GIP Agonist | Tirzepatide

Starting with lower dosessuch as the 0.25 mg weekly injectionallows your digestive system to adapt before advancing to higher maintenance doses

Since then, several GLP-1s for obesity have been approved for new indications such as secondary cardiovascular risk reduction (Wegovy), sleep apnea (Zepbound) and metabolic dysfunction-associated steatohepatitis or MASH (Wegovy)

This creates a vicious cycle of weight gain and inflammation

Results After exclusions and propensity score trimming, the cohort consisted of 145 410 patients who started GLP1 receptor agonist treatment and 291 667 patients who started DPP4 inhibitor treatment (fig 1)

BMJ Open 2024;14:e083550

Highlights Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) provide modest but clinically meaningful blood pressure (BP) lowering effects in people with hypertension and cardiometabolic comorbidities